What Type Of Shareholder Owns Heat Biologics, Inc.?s (NASDAQ:HTBX)?
Private Equity Ownership
With a stake of 6.2%, private equity firms could influence the HTBX board. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
: Brokerages Anticipate HTBX to Post ($0.14) Earning
Posted by Darrell McKinsey on Mar 17th, 2019
Heat Biologics Inc (NASDAQ:HTBX) has received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy recommendation. Brokers have set a 12 month consensus target price of $6.50 for the company and are predicting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also assigned Heat Biologics an industry rank of 73 out of 255 based on the ratings given to its competitors.
Posted by ABMN Staff on Mar 17th, 2019 // No Comments
CVI Holdings LLC purchased a new position in shares of Heat Biologics Inc (NASDAQ:HTBX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,557,768 shares of the biopharmaceutical company?s stock, valued at approximately $1,527,000. Heat Biologics comprises 3.4% of CVI Holdings LLC?s portfolio, making the stock its 6th biggest position. CVI Holdings LLC owned about 6.70% of Heat Biologics at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also bought and sold shares of HTBX. Northern Trust Corp purchased a new position in shares of Heat Biologics during the second quarter valued at approximately $111,000. Vanguard Group Inc. lifted its holdings in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company?s stock valued at $1,597,000 after purchasing an additional 136,256 shares during the last quarter. Vanguard Group Inc lifted its holdings in shares of Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company?s stock valued at $1,597,000 after purchasing an additional 136,256 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Heat Biologics during the fourth quarter valued at approximately $55,000. Hedge funds and other institutional investors own 16.39% of the company?s stock.
bestimmte Ereignisse als Prüfstein für Kursbewegungen zu sehen. Ist ja erstmal nur eine (weitere) Präsentation der bekannten Ergebnisse. Darüber hinaus allerdings ist es schon vielsagend, dass der Fokus von Heat offenbar in China liegt. Deshalb kann sich auch aus der morgigen Präsentation kurzfristig in der Folge natürlich etwas ergeben. Kann mir gut vorstellen, dass es mehrere Interessenten gibt, wie es das Unternehmen ja auch angibt.